Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia

Trial Profile

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Brexpiprazole (Primary) ; Quetiapine
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 17 Feb 2017 According to an Otsuka Pharmaceutical media release, brexpiprazole (Rexulti) has been approved by Health Canada based on data from this and two other phase III trials (700202951 and 700202559).
    • 05 Feb 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 13 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top